The reason for this study is to compare the effect of the study drug RAY1225 to semaglutide on blood sugar levels in participants with type 2 diabetes.
Have been diagnosed with type 2 diabetes mellitus (T2DM)
Have HbA1c between ≥7.0% and ≤11.5%
Have a body mass index (BMI) ≥20 kilograms per meter squared (kg/m²) at screening
Be of stable weight (±5%) for at least 12 weeks before screening
Have type 1 diabetes mellitus
Presence of severe chronic diabetic complications at screening, including but not limited to: proliferative diabetic retinopathy, diabetic macular edema, and severe non-proliferative diabetic retinopathy requiring acute treatment;
History of diabetic ketoacidosis or hyperosmolar hyperglycemic state within 24 weeks prior to randomization;
Occurrence of a Grade 3 hypoglycemic event within 12 months prior to screening, or ≥3 Grade 2 hypoglycemic events (venous or capillary blood glucose <3.0 mmol/L) within 3 months prior to screening, or presence of hypoglycemia-related symptoms ;